Notification That Annual Report Will Be Submitted Late (nt 10-k)
July 01 2019 - 5:30PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
12b-25
NOTIFICATION
OF LATE FILING
Commission
File Number:
333-201719
(Check
One):
|
[X]
Form 10-K
|
[ ]
Form 20-F
|
[ ]
Form 11-K
|
[ ]
Form 10-Q
|
[ ]
Form 10-D
|
|
[ ]
Form N-SAR
|
[ ]
Form N-CSR
|
|
|
For
Period Ended:
|
March
31, 2019
|
|
[ ]
Transition Report on Form 10-K
[ ]
Transition Report on Form 20-F
[ ]
Transition Report on Form 11-K
[ ]
Transition Report on Form 10-Q
[ ]
Transition Report on Form N-SAR
|
|
|
For
the Transition Period Ended:
|
|
Read
Instruction (on back page) Before Preparing Form. Please Print or Type.
Nothing
in this form shall be construed to imply that the Commission has verified any information contained herein.
If
the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:
PART
I — REGISTRANT INFORMATION
BIOTRICITY
INC.
Full Name of Registrant
Former
Name if Applicable
275
Shoreline Drive, Suite 150
Address
of Principal Executive Office
(Street and Number)
Redwood
City, California 94065
City,
State and Zip Code
PART
II — RULES 12b-25(b) AND (c)
If
the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule
12b-25(b), the following should be completed. (Check box if appropriate)
[X]
|
(a)
|
The
reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense
|
|
|
(b)
|
The
subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR,
or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject
quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be
filed on or before the fifth calendar day following the prescribed due date; and
|
|
|
|
(c)
|
The
accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.
|
PART
III — NARRATIVE
State
below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR, or the transition report or portion thereof,
could not be filed within the prescribed time period.
Biotricity
Inc. (the “Registrant”) files this report for a 15-day extension for filing its Annual Report on Form 10-K for the
period ended March 31, 2019 (“Form 10-K”). The Registrant will not be in a position to file its Form 10-K by the prescribed
filing date without unreasonable effort or expense due to the delay experienced by the Registrant in completing the audit of its
financial statements for the fiscal year ended March 31, 2019. The Registrant anticipates that it will file its Form 10-K no later
than the fifteenth (15th) calendar day following the prescribed filing date.
(Attach
extra Sheets if Needed)
PART
IV — OTHER INFORMATION
(1)
|
Name
and telephone number of person to contact in regard to this notification
|
John
Ayanoglou
|
|
800
|
|
590-4155
|
(Name)
|
|
(Area
Code)
|
|
(Telephone
Number)
|
(2)
|
Have
all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the
Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required
to file such report(s) been filed? If answer is no, identify report(s).
|
|
Yes
[X] No [ ]
|
(3)
|
Is
it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year
will be reflected by the earnings statements to be included in the subject report or portion thereof?
|
|
Yes
[ ] No [X]
|
|
|
|
If
so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons
why a reasonable estimate of the results cannot be made.
|
Biotricity
Inc.
(Name
of Registrant as Specified in Charter)
has
caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.
Date
|
July
1, 2019
|
By
|
/s/
John Ayanoglou
|
|
|
|
John
Ayanoglou, CFO
|
Biotricity (QB) (USOTC:BTCY)
Historical Stock Chart
From Feb 2025 to Mar 2025
Biotricity (QB) (USOTC:BTCY)
Historical Stock Chart
From Mar 2024 to Mar 2025